Adenosine Deaminase - a Novel Diagnostic and Prognostic Biomarker for Oral Squamous Cell Carcinoma

Deepak Chandrakant Kelgandre1*, Jigna Pathak1, Shilpa Patel2, Pramod Ingale3, Niharika Swain1

Abstract

Background: The number of patients with oral cancer in India is increasing gradually (especially in younger people). Although the diagnostic modalities and therapeutic management of oral cancer are improving, the treatment outcome and prognosis of oral cancer remain poor. The absence of definite early warning symptoms for most head and neck cancers suggests that sensitive and specific biomarkers are likely to be important in screening for high-risk patients. Aims: To analyze serum adenosine deaminase (ADA) levels in oral squamous cell carcinoma (OSCC) cases who reported to our institute. Materials and Methods: A prospective study was performed on 100 histopathologically proven cases of OSCC (study group) and 100 normal healthy individuals (control group). Independent sample and one sample t-tests and one way ANOVA followed by Tukey’s POST HOC test were conducted for analysis. Results: Statistically significant increase in serum ADA levels was observed in OSCC cases compared to the control group. Also serum ADA level increased significantly with the histopathological grade. Conclusions: Serum ADA levels in OSCC may be a useful diagnostic and prognostic biomarkers in clinical practice and our findings suggest that a large-scale study is warranted to confirm clinical utility as a prognostic and diagnostic biomarker.

Keywords: Oral SCC - adenosine deaminase - biomarker - prognosis
Deepak Chandrakant Kelgandre et al


OSCC.

The grading is based on the following Criteria: Degree of Keratinization, Cellular differentiation, Nuclear Changes, lymphoplasmablastic infiltration and the Invasive front. Based on the above mentioned criteria, study comprised (n=30) well differentiated, (n=30) moderately differentiated and (n=30) poorly differentiated OSCC cases. 90 age matched healthy individuals who had no history of any malignancy and infectious conditions in past six months were selected as a control group. 5 ml venous blood was collected from both the groups under the aseptic conditions after taking patients consent. Serum was separated by using centrifugation machine. Serum analysis for ADA was done in both the groups.

Adenosine deaminase assessment

Estimation of serum ADA level was done by using calorimetric method of Galanti and Guisti (Guesti G, 1974). Adenosine Deaminase hydrolyses adenosine to ammonia and inosine. The ammonia further formed reacts with a phenol and hypochlorite in an alkaline medium to form a blue indophenol complex with sodium nitroprusside acting as a catalyst. Intensity of blue colored indophenol complex formed is directly proportional to the amount of ADA present in the sample.

The procedure was as follows: i). All the reagent and sample was brought to room temperature before use; ii). Working phenol reagent and working hypochlorite reagents were prepared; iii). Calorimeter was set with filter of 570-630 nm at 37°C. iv). Four clean dry test tube were labeled as reagent blank (B), standard(S), sample blank (SB), sample or test (T); v). Addition of reagent into these test tube was done as follows; vi). It was mixed well and incubated at 37°C for exactly 60 minutes, and then following reagents were added; vii). It was mixed well and incubated at 37°C for 30 minutes; viii). Absorbance (optical densities) of the reagent blank (Abs.B), standard (Abs.S), sample blank (Abs.SB), sample or test (Abs.T) was measured by using the calorimeter; ix).

Calculation

All collected data was entered into a SPSS 17.0 Analysis was done using statistical tests such as independent Sample t-test, one Sample t-test and one way ANOVA followed by Tuckey’s POST HOC test wherever applicable. The level of significance was set at 5%. All p-values less than 0.05 were treated as a significant.

Results

Table1 provides a comparison of mean serum ADA level of control group with OSCC group and Table 2 multiple comparisons of mean serum ADA level of control group with different histopathological grades of OSCC.

Photomicrographs of histopathology of different lesions are given in Figure 1. When serum ADA level of control group was compared with well moderate and poorly differentiated OSCC group P value was 0.00 (<0.05) hence was statistically highly significant. When serum ADA level of well differentiated group was compared with moderately and poorly differentiated OSCC group P value was 0.00 (<0.05) and hence was statistically highly significant. When serum ADA level of moderately differentiated group was compared with poorly differentiated OSCC group P value was 0.164 (>0.00) and hence was statistically insignificant.

Figure 2 demonstrates mean serum ADA levels in each group. There is an increase in serum ADA levels from control to poorly differentiated OSCC.

Table 1. Comparison of Mean Serum ADA Level of Control Group with OSCC Group

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Mean</th>
<th>SD</th>
<th>Mean Difference</th>
<th>t-stat</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>OSCC Group</td>
<td>90</td>
<td>31.1953</td>
<td>4.171</td>
<td>11.297</td>
<td>14.34</td>
<td>&lt; 0.001**</td>
</tr>
<tr>
<td>Control Group</td>
<td>90</td>
<td>19.8983</td>
<td>1.106</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

** Highly significant difference

Figure 1. Histopathological Examination of OSCCs. A & B: Well differentiated, C: Moderately differentiated and D: Poorly differentiated grade

Figure 1. Mean serum ADA Levels in Each Group. There is an increase in serum ADA levels from control to poorly differentiated OSCC.
Adenosine Deaminase - a Novel Diagnostic and Prognostic Biomarker for Oral SCC

Table 2. Multiple Comparisons of Mean Serum ADA Level of control group with different histopathological grades of OSCC

<table>
<thead>
<tr>
<th>(I) Group</th>
<th>(J) Group</th>
<th>Mean Difference (I-J)</th>
<th>Std. Error</th>
<th>Sig. (p value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control Group</td>
<td>Well Differentiated</td>
<td>-7.75067*</td>
<td>0.89873</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Moderately Differentiated</td>
<td>-12.29367*</td>
<td>0.89873</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Poorly Differentiated</td>
<td>-13.84667*</td>
<td>0.89873</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Control Group</td>
<td>7.75067*</td>
<td>0.89873</td>
<td>0</td>
</tr>
<tr>
<td>Well Differentiated</td>
<td>Moderately Differentiated</td>
<td>-4.54300*</td>
<td>1.10072</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Poorly Differentiated</td>
<td>-6.09600*</td>
<td>1.10072</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Control Group</td>
<td>12.29367*</td>
<td>0.89873</td>
<td>0</td>
</tr>
<tr>
<td>Moderately Differentiated</td>
<td>Well Differentiated</td>
<td>4.54300*</td>
<td>1.10072</td>
<td>0.164</td>
</tr>
<tr>
<td></td>
<td>Poorly Differentiated</td>
<td>-1.553</td>
<td>1.10072</td>
<td>0.164</td>
</tr>
<tr>
<td></td>
<td>Control Group</td>
<td>13.84667*</td>
<td>0.89873</td>
<td>0</td>
</tr>
<tr>
<td>Poorly Differentiated</td>
<td>Well Differentiated</td>
<td>6.09600*</td>
<td>1.10072</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Moderately Differentiated</td>
<td>1.553</td>
<td>1.10072</td>
<td>0.164</td>
</tr>
</tbody>
</table>

Discussion

OSCC is one of the most common malignancies in the world. Oral and pharyngeal cancer, grouped together is the sixth leading cancer in the world and ranks in the top three in high incidence areas (Saman Warnakulasuriya, 2009). It traditionally carries a poor prognosis with more than 50% of the cases diagnosed at an advanced stage, with the five year survival rate remaining low at ~30 to 50% (Saman Warnakulasuriya, 2009). Lack of noninvasive and reliable screening test has been quoted as the main reason. In this scenario minimally invasive cancer specific tests are urgently sought and recently serological tumor markers have been included and actively pursued to obtain an easy, simple and reliable diagnostic tool for the detection of oral cancer. Serum analysis of various biochemical markers in cancer has diagnostic and prognostic significance. There are a number of tumor markers studied which can be used in the diagnosis and prognosis of oral cancer, however none of these markers have a consistent sensitivity and specificity and hence the pursuit for newer markers has continued.

It has been known for many years that the enzyme complement of a tumor cell differs in many ways from that of its normal counterpart reflecting its altered metabolism. Elevated enzyme levels in cancer patients denote aggressiveness of cancer, unchanged or increasing levels indicating a lack of response, also decrease to normal levels following successful treatment (M.M. Suchitra et al., 2009). Serum enzymes are useful for monitoring the effects of therapy, to detect recurrences and also have prognostic value as their level frequently reflects tumor burden. ADA an enzyme of the purine salvage pathway is widely distributed in tissues. Many studies have demonstrated alterations of ADA activity in the tumor tissue and serum in patients with lung, head and neck, breast and ovarian cancer (Mini, 1995; Selda et al, 1996; Pragathi et al., 2005; Ashok et al., 2008). It catalyses hydrolytic deamination of adenosine to inosine and 2'-deoxy adenosine to 2'-deoxy inosine respectively. Numerous studies have documented an increase of ADA in very rapidly growing malignancies, where it has been documented as a serological tumor marker, while slow growing well differentiated tumors do not express pronounced ADA activity (Balis, 1985).

The normal serum ADA level in healthy individuals ranges from 18 to 22 IU/L. In our study we found that the serum ADA level in all control group individuals were within the normal range (mean 19.90 IU/L). Mean serum ADA level in study group was 31.20 IU/L. Our results showed the statistically significant increased serum ADA levels in study group as compared to control group which is in agreement with the study done by Harbans Lal (1987), R. Mishra (2000), Kalcigolu MT (2004), Ashok K J (2008) and Rakesh Dhanhkar (2011). Kalcigolu MT in 2004 showed that serum ADA level was increased significantly in OSCC, thus suggested that serum ADA activity may be helpful in the diagnosis and follow-up of head and neck cancers. Rakesh Dhanhkar (2011) found that levels of adenosine deaminase, uric acid, and C-reactive protein were significantly higher in patients of head and neck cancers as compared to the levels in controls.

Various studies on gastric, colorectal, breast, bladder, and ovarian cancers reported the increase in serum ADA level. Mini Walia et al. (1995) found a significantly (p<0.001) increased level of serum ADA in breast cancer patients compared to normal individuals, thus they suggested that serum ADA can be a useful parameter for diagnosing breast cancer and for monitoring its progression. Pragathi, P. et al in 2005 showed a significant increase in serum ADA levels in the ovarian cancer group but not in the benign group when compared to controls. They suggested that the elevated levels were certainly due to the presence of cancer cells, and thus it can serve as a parameter to differentiate malignant conditions from the benign tumors of the ovary.
In our study mean serum ADA level in well, moderate and poorly differentiated grade were 27.3 IU/L, 31.8 IU/L and 33.5 IU/L respectively. We found that serum ADA level gradually increased from well, moderate to poorly differentiated OSCC grade. Statistically significant difference was present between well & moderate grade, and between well & poor grade, but insignificant difference between moderate & poor grade. In the literature previous studies mentioned the correlation of serum ADA level with different clinical stages of oral cancer. To the best of our knowledge no study correlated the serum ADA levels with different histopathological grades. Harbans Lal et al in 1987 evaluated the serum ADA in 40 OSCC patients of different stages and found the ADA activity is increased with advancement in the clinical stage of the cancer. Study done by R. Mishra et al. (2000) found significant correlation between increased levels of ADA with lymph node involvement and concluded that this may help in assessing the decrease in tumor mass and improvement in patient & clinical condition. Ashok et al in 2008 found that there was a highly significant correlation between the serum ADA level and the increasing disease stage (severity of the disease), the tumor status and metastasis of the tumor to the neck nodes. They concluded that Serum ADA levels can be used as one of the diagnostic tools in head and neck cancer.

ADA is an enzyme of the purine salvage pathway. ADA is present on the cell surface as well as intra-cellularly, but it does not have its own transmembrane domain and is associated with CD26, a surface glycoprotein with dipeptidyl peptidase IV activity (Franco, 1997). Due to the rapid growth, solid tumors routinely experience severe hypoxia and necrosis leading to adenine nucleotide degradation and adenosine release (Linden, 2006). The released adenosine constitutes supportive environment for tumor growth by means of protection against ischemia. At the same time it stimulates the growth and angiogenesis as well as suppresses immune response. So increase in adenosine production leads to increase in production of ADA. Also, in cancer there is an increased turnover of malignant cells and an associated increase in nucleotide metabolism leading to an increase in purine metabolizing enzymes. ADA is particularly sensitive to stimulation by growth factors and cytokines during rapid tissue proliferation such as IL-2, IL12 and INFγ which increases during malignancy (Ashok et al., 2008).

Results of our study showed that serum ADA level increases significantly in OSCC as compared to control group. It shows that nucleotide (purine & pyrimidine) metabolism increases in OSCC due to increase in DNA turnover, and serum level increases because of leakage of enzyme from primary malignant cells and lymphatic metastasis. In the literature it is mentioned that the prognosis of OSCC worsened from well to poorly differentiated grade, also serum ADA is known to increase with disease progression. In our study, serum ADA level increased from well to moderate to poorly differentiated OSCC. Therefore it can be suggested that serum ADA can be used as a diagnostic and also prognostic biomarker for OSCC. Also the simplicity of measuring ADA activity combined with its cost effectiveness gives an added advantage to consider ADA as a tumor marker in oral cancer. However, during evaluation of serum ADA level one has to keep in mind that the level of these markers altered in different systemic conditions such as various cancers, infections etc, and so these factors should be ruled out.

Thus, from our study observations it is seen that, serum ADA level increases in OSCC, also the level of these markers increases according to histopathological grade. Hence we propose that serum ADA can be used as a diagnostic as well as prognostic bio-marker in OSCC.

References


